Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2024.1383797 Immunology Correction Corrigendum: Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications Liu Yun 1 † Tong Hanwen 1 † He Fei 1 † Zhai Yu 1 Wu Chao 2 * Wang Jun 1 * Jiang Chenxiao 3 * 1 Department of Emergency Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China 2 Department of Infectious Disease, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China 3 Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Edited by: Keun Hwa Lee, Hanyang University, Republic of Korea

Reviewed by: Jeong Rae Yoo, Jeju National University, Republic of Korea

*Correspondence: Chenxiao Jiang, sharejcx@163.com; Jun Wang, wjgaogou@aliyun.com; Chao Wu, dr.wu@nju.edu.cn

†These authors have contributed equally to this work

 05 04 2024 2024 15 1383797 08 02 2024 25 03 2024 Copyright © 2024 Liu, Tong, He, Zhai, Wu, Wang and Jiang 2024 Liu, Tong, He, Zhai, Wu, Wang and Jiang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications By Liu Y, Tong H, He F, Zhai Y, Wu C, Wang Jand Jiang C (2023). Front. Immunol. 14:1118039. doi: 10.3389/fimmu.2023.1118039 intravenous immunoglobulin mortality severe fever with thrombocytopenia syndrome neurological complications dosage duration section-in-acceptance Viral Immunology

In the published article, there was an error in Figure 2 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Figure 2 and its caption Comparison of (A) IVIG dosage and (B) IVIG duration between the survival group and the death group. **P <0.01. appear below.

Comparison of (A) IVIG dosage and (B) IVIG duration between the survival group and the death group. **P <0.01.

In the published article, there was an error in Figure 4 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Figure 4 and its caption Kaplan–Meier curves estimating 28-day mortality in SFTS patients based on (A) IVIG dosage and (B) IVIG duration. appear below.

Kaplan–Meier curves estimating 28-day mortality in SFTS patients based on (A) IVIG dosage and (B) IVIG duration.

In the published article, there was an error in Table 1 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Table 1 and its caption Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups. appear below.

Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups.

Variable Survival(n = 36) Death(n = 26) P-value
Demographics
Age, years 67 (54-73) 71 (58-76) 0.199
Male, n (%) 18 (50.0%) 11 (42.3%) 0.549
Chronic comorbidities, n (%)
Hypertension 11 (30.6%) 10 (38.5%) 0.516
Diabetes mellitus 3 (8.3%) 2 (7.7%) 1.000
Malignancy 1 (2.78%) 0 (0%) 1.000
CAD 1 (2.78%) 0 (0%) 1.000
COPD 0 (0%) 1 (3.85%) 0.419
Clinical manifestations, n (%)
Nausea 12 (33.3%) 7 (26.9%) 0.589
Vomiting 10 (27.8%) 9 (34.6%) 0.564
Celialgia 4 (11.1%) 2 (7.7%) 0.653
Diarrhea 17 (47.2%) 10 (38.5%) 0.492
Unintelligible speech 1 (2.8%) 3(11.5%) 0.300
Dizziness and headache 18 (50.0%) 6 (23.1%) 0.032
Cough 9 (25.0%) 4 (15.4%) 0.359
Sputum 7 (19.4%) 3 (11.5%) 0.627
Chest tightness 3 (8.3%) 3 (11.5%) 0.689
Rash 6 (16.7%) 1 (3.8%) 0.222
Lymphadenopathy 13 (36.1%) 7 (26.9%) 0.445
Bleeding spots on the skin 7 (19.4%) 9 (34.6%) 0.178
Laboratory parameters
WBC count, median (IQR),×109/L 2.5 (1.8-4.6) 2.7 (1.7-3.7) 0.898
ANC count, median (IQR), ×109/L 1.7 (1.0-2.9) 2.1 (1.2-2.8) 0.668
ALC count, median (IQR), ×109/L 0.7 (0.4-0.9) 0.5 (0.3-0.6) 0.042
NLR, median (IQR) 2.2 (1.5-6.1) 3.3 (1.9-9.1) 0.136
RDW, median (IQR), % 13.2 (12.8-13.5) 13.6 (12.8-14.3) 0.071
PLT count, median (IQR), ×109/L 44.5 (33.8-61.3) 39.5 (29.0-58.5) 0.480
PLR, median (IQR) 65.5 (39.3-146) 89.6 (67.5-145.0) 0.248
PT, median (IQR), s 12.0 (11.2-12.6) 12.4 (11.7-13.0) 0.123
APTT, median (IQR), s 41.4 (33.6-46.3) 48.5 (37.6-61.1) 0.009
TT, median (IQR), s 22.8 (21.1-27.7) 26.9 (21.8-57.9) 0.057
D-dimer, median (IQR), mg/L 3.8 (2.3-9.2) 9.9 (3.4-22.6) 0.018
ALT, median (IQR), U/L 69.6 (54.3-97.2) 75.3 (50.5-90.5) 0.881
AST, median (IQR), U/L 172.5 (93.4-312.9) 222.0 (114.1-321.8) 0.304
ALB, median (IQR), g/L 32.0 (28.7-35.7) 31.7 (29.1-34.1) 0.775
TBIL, median (IQR), µmol/L 11.0 (8.6-13.9) 7.7 (5.8-11.5) 0.066
SCr, median (IQR), µmol/L 72.5 (48.8-89.6) 82 (67.5-123.6) 0.090
BUN, median (IQR), mmol/L 5.2 (3.5-7.1) 5.9 (4.8-10.6) 0.061
UA, median (IQR), µmol/L 306 (236-347) 342 (231-463) 0.471
IVIG usage
IVIG dosage, g 95.0 (57.5-100.0) 60.0 (40.0-100.0) 0.066
IVIG duration, d 5 ± 2 4 ± 2 0.003
Additional information
Time from onset to arriving in hospital, d 7 ± 3 7 ± 2 0.317
Time from onset to IVIG treatment, d 9 ± 3 9 ± 3 0.677

CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; RDW, red cell volume distribution width; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; IVIG, intravenous immunoglobulin; IQR, interquartile range.

In the published article, there was an error. The unit of IVIG dosage was displayed as “mg”.

A correction has been made to Introduction, Paragraph Number 161. This sentence previously stated:

“Ultimately, we determined that an IVIG dosage of more than or equal to 80 mg through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”

The corrected sentence appears below:

“Ultimately, we determined that an IVIG dosage of more than or equal to 80 g through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”

A correction has been made to Results, Paragraph Number 694. This sentence previously stated:

“Patients with an IVIG dosage of more than or equal to 80 mg (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”

The corrected sentence appears below:

“Patients with an IVIG dosage of more than or equal to 80 g (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”

A correction has been made to Discussion, Paragraph Number 884. This sentence previously stated:

“In this study, our findings suggested that higher dosages (≥80 mg) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”

The corrected sentence appears below:

“In this study, our findings suggested that higher dosages (≥80 g) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”

The authors apologize for the errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.